Economic Evaluation of 10% Intravenous Immunoglobulin In Treatment of Primary Immunodeficiencies In Adults In The Russian Federation

OBJECTIVES:To conduct cost-minimization analysis of 10% liquid intravenous immunoglobulin (IVIG) compared with IVIGs of 5% concentration in treatment of primary immunodeficiencies (PID) in adults in Russia for 1-year period. METHODS: A cost-minimization model was developed in Excel 2013 to simulate the direct and indirect costs for 1-year period. Costs included ones for treatment course with IVIGs and IVIG administration, expenditures of infections' treatment, ones associated with storage and transportation of IVIG, disability pensions and payments for sick leave due to illness of the patient, GDP loss due to disability. Differences In costs are explained by the various duration of IVIG administration, the differences in the average price per 1 g IVIG and storage conditions. RESULTS: According to the cost-minimization analysis, 10% IVIG (Switzerland) therapy (1,507,564 rubles/26,435 $) is the least costly by the end of the 1st year per 1 patient. Therapy with 5% IVIG (Italy) costs 1,576,504 rubles/27,643 $, 5% IVIG (Austria) and 5% IVIG (Germany) cost 1,678,417 rubles/29,430 $ and 1,967,457 rubles/34,499 $ consequently. Current rate taken as for 15.06.2017 is 1$ = 57,03 RUB. CONCLUSIONS: Cost-minimization analysis reveals that the use of the 10% liquid intravenous immunoglobulin (Switzerland) is the most cost-saving scheme of therapy of primary immunodeficiency in adults population in the conditions of the healthcare of the Russian Federation for 1-year period.